It's time to overcome the "One-Size-Fits-All" approach in chronic coronary syndrome?

Chronic coronary syndrome (CCS) refers to a wide spectrum of clinical conditions characterized by clinically stable progression of coronary artery disease (CAD) [1]. Current guidelines recommend the administration of dual antiplatelet therapy (DAPT) with cardioaspirin and clopidogrel for 6 months for patients undergoing elective percutaneous coronary intervention (PCI) [1]. However, patients with CCS represent a heterogeneous population and the type and duration of DAPT can be modulated weighting the individual ischemic and hemorrhagic risks [1].
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research